Differential gene expression profile associated to apoptosis induced by dexamethasone in CLL cells according to IGHV/ZAP-70 status

Clinical Cancer Research

Volumn 18, Issue 21, 2012, Pages 5924-5933

  Baptista, Maria Joao ^a   Muntanõla, Ana ^b   Calpe, Eva ^a   Abrisqueta, Pau ^a   Salamero, Olga ^a   Fernańdez, Eva ^c   Codony, Carles ^c   Giné, Eva ^c   Kalko, Susana G ^d   Crespo, Marta ^a   Bosch, Francesc ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; DEXAMETHASONE; FK 506 BINDING PROTEIN; GLUCOCORTICOID INDUCED LEUCINE ZIPPER PROTEIN; LEUCINE ZIPPER PROTEIN; PROTEIN KINASE ZAP 70; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SENSITIVITY; EX VIVO STUDY; GENE ACTIVITY; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC REGULATION; HUMAN; HUMAN CELL; IGHV GENE; LEUKEMIA CELL; MOLECULAR DYNAMICS; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CLUSTER ANALYSIS; DEXAMETHASONE; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; TACROLIMUS BINDING PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTOME; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84868581222     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2771     Document Type: Article

References (50)

1. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, et al. Longterm results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975-80.
2. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-74.
3. Bosch F, Abrisqueta P, Villamor N, Terol MJ, Gonzalez-Barca E, Ferra C, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009;27:4578-84.
4. Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCMR) in frontline CLL <70 Years. Leuk Res 2010;34:284-8.
5. Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzuMab, and rituximab for high-risk chronic lymphocytic leukemia. Blood 2011;118:2062-8.
6. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6. (Pubitemid 32064784)
7. Gonzalez D, Martinez P, Wade R, Hockley S, Oscier D, Matutes E, et al. Mutational status of the TP53 gene as a predictor of response and survival in patientswith chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011;29:2223-9.
8. Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J, et al. Alemtuzu Mab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278-81. (Pubitemid 38525651)
9. Stilgenbauer S, Zenz T, Winkler D, Buhler A, Schlenk RF, Groner S, et al. Subcutaneous alemtuzuMab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27:3994-4001.
10. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical ef ficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109:399-404. (Pubitemid 46105932)
11. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009;27:6012-8.
12. Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of fl avopiridol in relapsed chronic lymphocytic leukemia. Blood 2009;113:2637-45.
13. Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291-7.
14. Sher T, Miller KC, Lawrence D, Whitworth A, Hernandez-Ilizaliturri F, Czuczman MS, et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma 2010;51:85-8.
15. Bosanquet AG, McCann SR, Crotty GM, Mills MJ, Catovsky D. Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay. Acta Haematol 1995;93:73-9.
16. Thornton PD, Hamblin M, Treleaven JG, Matutes E, Lakhani AK, Catovsky D. High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. Leuk Lymphoma 1999;34:167-70. (Pubitemid 29248672)
17. Thornton PD, Matutes E, Bosanquet AG, Lakhani AK, Grech H, Ropner JE, et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003;82:759-65. (Pubitemid 38008843)
18. Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006;20:1441-5. (Pubitemid 44084061)
19. Bowen DA, Call TG, Jenkins GD, Zent CS, Schwager SM, Van Dyke DL, et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007;48:2412-7. (Pubitemid 350253473)
20. Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008;22:2048-53.
21. Dungarwalla M, Evans SO, Riley U, Catovsky D, Dearden CE, Matutes E. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 2008;93:475-6. (Pubitemid 351398657)
22. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-56.
23. Baxter JD, Tomkins GM. Specific cytoplasmic glucocorticoid hormone receptors in hepatoma tissue culture cells. Proc Natl Acad Sci U S A 1971;68:932-7.
24. Davies TH, Ning YM, Sanchez ER. A new first step in activation of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins. J Biol Chem 2002;277:4597-600. (Pubitemid 34968486)
25. Planey SL, Abrams MT, Robertson NM, Litwack G. Role of apical caspases and glucocorticoid-regulated genes in glucocorticoid-induced apoptosis of pre-B leukemic cells. Cancer Res 2003;63:172-8. (Pubitemid 36070437)
26. Wang Z, Malone MH, He H, McColl KS, Distelhorst CW. Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J Biol Chem 2003;278:23861-7. (Pubitemid 36830212)
27. Holleman A, Cheok MH, Den Boer ML, Yang W, Veerman AJ, Kazemier KM, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004;351:533-42.
28. Schmidt S, Rainer J, Riml S, Ploner C, Jesacher S, Achmuller C, et al. Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia. Blood 2006;107:2061-9. (Pubitemid 43292367)
29. Wang Z, Rong YP, Malone MH, Davis MC, Zhong F, Distelhorst CW. Thioredoxin-interacting protein (txnip) is a glucocorticoid-regulated primary response gene involved in mediating glucocorticoid-induced apoptosis. Oncogene 2006;25:1903-13.
30. Tissing WJ, Den Boer ML, Meijerink JP, Menezes RX, Swagemakers S, van der Spek PJ, et al. Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. Blood 2007;109:3929-35. (Pubitemid 46646638)
31. Iglesias-Serret D, de FM, Santidrian AF, Coll-Mulet L, Cosialls AM, Barragan M, et al. Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells. Leukemia 2007;21:281-7.
32. Kivekas I, Tobin G, Thunberg U, Vilpo L, Sundstrom C, Rosenquist R, et al. Ex vivodrug and irradiation sensitivities in hypermutated and unmutated forms of chronic lymphocytic leukemia cells. Leuk Res 2003;27:337-41. (Pubitemid 36071391)
33. Aleskog A, Tobin G, Laurell A, Thunberg U, Lindhagen E, Roos G, et al. VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia. Eur J Haematol 2004;73:407-11. (Pubitemid 39564363)
34. Boelens J, Lust S, Van BF, Van GM, Janssens A, Derycke L, et al. Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia. Leuk Res 2009;33:1335-43.
35. Lindhagen E, Norberg M, Kanduri M, Tobin G, Saisanen L, Aberg M, et al. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia-rolipram and prednisolone active in cells from patients with poor prognosis. Eur J Haematol 2009;83:22-34.
36. Bellosillo B, Dalmau M, Colomer D, Gil J. Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells. Blood 1997;89:3378-84. (Pubitemid 27229825)
37. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-75. (Pubitemid 36514707)
38. McCall MN, Bolstad BM, Irizarry RA. Frozen robust multiarray analysis (fRMA). Biostatistics 2010;11:242-53.
39. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, Howe EA, et al. TM4 microarray software suite. Methods Enzymol 2006;411:134-93.
40. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression inmicroarray experiments. Stat Appl Genet Mol Biol 2004;3:Article3.
41. Huang dW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
42. Erlacher M, Michalak EM, Kelly PN, Labi V, Niederegger H, Coultas L, et al. BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo . Blood 2005;106:4131-8. (Pubitemid 41775918)
43. Bachmann PS, Gorman R, Mackenzie KL, Lutze-Mann L, Lock RB. Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor. Blood 2005;105:2519-26. (Pubitemid 40387054)
44. Lu J, Quearry B, Harada H. p38-MAP kinase activation followed by BIM induction is essential for glucocorticoid-induced apoptosis in lymphoblastic leukemia cells. FEBS Lett 2006;580:3539-44. (Pubitemid 44208999)
45. Wang JC, Derynck MK, Nonaka DF, Khodabakhsh DB, Haqq C, Yamamoto KR. Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes. Proc Natl Acad Sci U S A 2004;101:15603-8. (Pubitemid 39473534)
46. Ayroldi E, Zollo O, Bastianelli A, Marchetti C, Agostini M, Di VR, et al. GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signaling. J Clin Invest 2007;117:1605-15. (Pubitemid 46871345)
47. Paquet C, Schmitt E, Beauchemin M, Bertrand R. Activation of multidomain and BH3-only pro-apoptotic Bcl-2 family members in p53-defective cells. Apoptosis 2004;9:815-31. (Pubitemid 40941210)
48. Gruber G, Carlet M, Turtscher E, Meister B, Irving JA, Ploner C, et al. Levels of glucocorticoid receptor and its ligand determine sensitivity and kinetics of glucocorticoid-induced leukemia apoptosis. Leukemia 2009;23:820-3.
49. Grugan KD, Ma C, Singhal S, Krett NL, Rosen ST. Dual regulation of glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-kinase/AKT pathways in multiple myeloma. J Steroid Biochem Mol Biol 2008;110:244-54.
50. Bachmann PS, Gorman R, Papa RA, Bardell JE, Ford J, Kees UR, et al. Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia. Cancer Res 2007;67:4482-90. (Pubitemid 46815099)